All In Biotech

Drug Trial Radar · NCT00152022

Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.

A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).

Last checked: Nov 19, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Apr 25, 2005

Primary completion

Nov 4, 2005

Study completion Nov 4, 2005

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also look at how SPD465 affects the participants sleep and how they perceive their quality of life.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

  • Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Baseline (following ADHD medication washout of 7-28 days)
  2. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 1
  3. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 2
  4. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 3
  5. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 4
  6. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 5
  7. The primary measure of efficacy will be the clinician-administered ADHD-rating scale (ADHD-RS-IV)Time frame: Week 6

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.